260 related articles for article (PubMed ID: 27469377)
1. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
[TBL] [Abstract][Full Text] [Related]
2. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study.
Boillat-Blanco N; Darling KE; Schoni-Affolter F; Vuichard D; Rougemont M; Fulchini R; Bernasconi E; Aouri M; Clerc O; Furrer H; Günthard HF; Cavassini M;
Antivir Ther; 2015; 20(2):165-75. PubMed ID: 24964403
[TBL] [Abstract][Full Text] [Related]
3. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals.
De Luca A; Ciancio BC; Larussa D; Murri R; Cingolani A; Rizzo MG; Giancola ML; Ammassari A; Ortona L
Neurology; 2002 Aug; 59(3):342-7. PubMed ID: 12177366
[TBL] [Abstract][Full Text] [Related]
4. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
Mukerji SS; Misra V; Lorenz DR; Uno H; Morgello S; Franklin D; Ellis RJ; Letendre S; Gabuzda D
Clin Infect Dis; 2018 Sep; 67(8):1182-1190. PubMed ID: 29617912
[TBL] [Abstract][Full Text] [Related]
5. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
6. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
[TBL] [Abstract][Full Text] [Related]
8. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
[TBL] [Abstract][Full Text] [Related]
9. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients.
Antinori A; Giancola ML; Grisetti S; Soldani F; Alba L; Liuzzi G; Amendola A; Capobianchi M; Tozzi V; Perno CF
AIDS; 2002 Sep; 16(14):1867-76. PubMed ID: 12351946
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic HIV CNS viral escape among patients on effective cART.
Manesh A; Barnabas R; Mani S; Karthik R; Abraham OC; Chacko G; Kannangai R; Varghese GM
Int J Infect Dis; 2019 Jul; 84():39-43. PubMed ID: 30951880
[TBL] [Abstract][Full Text] [Related]
13. Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.
Stephan C; Bartha V; Herrmann E; von Hentig N; Khaykin P; Knecht G; Gute P; Brodt HR; Stürmer M; Berger A; Bickel M
Med Microbiol Immunol; 2013 Apr; 202(2):117-24. PubMed ID: 22983722
[TBL] [Abstract][Full Text] [Related]
14. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
[TBL] [Abstract][Full Text] [Related]
15. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue.
Ruiz L; van Lunzen J; Arno A; Stellbrink HJ; Schneider C; Rull M; Castellà E; Ojanguren I; Richman DD; Clotet B; Tenner-Racz K; Racz P
AIDS; 1999 Jan; 13(1):F1-8. PubMed ID: 10207538
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
17. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
[TBL] [Abstract][Full Text] [Related]
19. Analysis of correlation between cerebrospinal fluid and plasma HIV-1 RNA levels in patients with neurological opportunistic diseases.
Christo PP; Greco DB; Aleixo AW; Livramento JA
Rev Inst Med Trop Sao Paulo; 2011; 53(4):193-6. PubMed ID: 21915461
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
Hoppe A; Giuliano M; Lugemwa A; Thompson JA; Floridia M; Walker AS; Senoga I; Abwola MC; Pirillo MF; Kityo CM; Arenas-Pinto A; Paton NI;
Antivir Ther; 2018; 23(2):191-195. PubMed ID: 29021409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
